Home LiteratureArticle Details
PMID: 28805815 Published · ppublish English Journal Article

AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.

Nature neuroscience ·Vol. 20 ·No. 10 ·2017-10-00 ·Pages 1329-1341

Chow RD, Guzman CD, Wang G, Schmidt F, Youngblood MW, Ye L, Errami Y, Dong MB, Martinez MA, Zhang S, Renauer P, Bilguvar K, Gunel M, Sharp PA, Zhang F, Platt RJ, Chen S

Abstract

A causative understanding of genetic factors that regulate glioblastoma pathogenesis is of central importance. Here we developed an adeno-associated virus-mediated, autochthonous genetic CRISPR screen in glioblastoma. Stereotaxic delivery of a virus library targeting genes commonly mutated in human cancers into the brains of conditional-Cas9 mice resulted in tumors that recapitulate human glioblastoma. Capture sequencing revealed diverse mutational profiles across tumors. The mutation frequencies in mice correlated with those in two independent patient cohorts. Co-mutation analysis identified co-occurring driver combinations such as B2m-Nf1, Mll3-Nf1 and Zc3h13-Rb1, which were subsequently validated using AAV minipools. Distinct from Nf1-mutant tumors, Rb1-mutant tumors are undifferentiated and aberrantly express homeobox gene clusters. The addition of Zc3h13 or Pten mutations altered the gene expression profiles of Rb1 mutants, rendering them more resistant to temozolomide. Our study provides a functional landscape of gliomagenesis suppressors in vivo.

MeSH Terms
Animals Brain Neoplasms/drug therapy,genetics CRISPR-Cas Systems Cells, Cultured DNA Mutational Analysis Dacarbazine/analogs & derivatives,therapeutic use Dependovirus/genetics Female Gene Knock-In Techniques Gene Knockout Techniques Glioblastoma/drug therapy,genetics Humans Male Mice Mutation Suppression, Genetic/genetics Temozolomide Transcriptome/genetics
Chemicals
Dacarbazine Temozolomide
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Chow Ryan D ORCID
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA. | Medical Scientist Training Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Guzman Christopher D
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA. | Biological and Biomedical Sciences Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Immunobiology Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Wang Guangchuan
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA.
Schmidt Florian
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. | Department of Chemistry, University of Basel, Basel, Switzerland.
Youngblood Mark W
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Medical Scientist Training Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA.
Ye Lupeng
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA.
Errami Youssef
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA.
Dong Matthew B
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA. | Medical Scientist Training Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Martinez Michael A
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA.
Zhang Sensen
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA.
Renauer Paul
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA. | Biological and Biomedical Sciences Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Bilguvar Kaya
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Yale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA.
Gunel Murat
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Medical Scientist Training Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA. | Yale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA.
Sharp Phillip A
Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts, USA. | Department of Biology, MIT, Cambridge, Massachusetts, USA.
Zhang Feng
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. | Department of Biological Engineering, MIT, Cambridge, Massachusetts, USA.
Platt Randall J ORCID
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. | Department of Chemistry, University of Basel, Basel, Switzerland.
Chen Sidi ORCID
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA. | Systems Biology Institute, Yale University School of Medicine, West Haven, Connecticut, USA. | Medical Scientist Training Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Biological and Biomedical Sciences Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Immunobiology Program, Yale University School of Medicine, New Haven, Connecticut, USA. | Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA. | Stem Cell Center, Yale University School of Medicine, New Haven, Connecticut, USA.
References (66)
66 references, click to expand
  1. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Lancet Oncol. 2009 May;10 (5):459-66 PMID: 19269895
  2. Long-term survival with glioblastoma multiforme.
    Brain. 2007 Oct;130(Pt 10):2596-606 PMID: 17785346
  3. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.
    Cancer Cell. 2011 Mar 8;19(3):305-16 PMID: 21397855
  4. Near-optimal probabilistic RNA-seq quantification.
    Nat Biotechnol. 2016 May;34(5):525-7 PMID: 27043002
  5. A restricted cell population propagates glioblastoma growth after chemotherapy.
    Nature. 2012 Aug 23;488(7412):522-6 PMID: 22854781
  6. Cancer: The blind spot of p53.
    Nature. 2010 Nov 25;468(7323):519-20 PMID: 21107421
  7. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy.
    Br J Cancer. 2017 Jan 17;116(2):149-155 PMID: 27884017
  8. Mutational landscape and significance across 12 major cancer types.
    Nature. 2013 Oct 17;502(7471):333-339 PMID: 24132290
  9. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.
    Bioinformatics. 2010 Jan 1;26(1):139-40 PMID: 19910308
  10. Genomic characterization of recurrent high-grade astroblastoma.
    Cancer Genet. 2016 Jul-Aug;209(7-8):321-30 PMID: 27425854
  11. Genetically engineered mouse models of brain cancer and the promise of preclinical testing.
    Brain Pathol. 2009 Jan;19(1):132-43 PMID: 19076778
  12. Maximizing mouse cancer models.
    Nat Rev Cancer. 2007 Sep;7(9):645-58 PMID: 17687385
  13. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.
    Nat Rev Cancer. 2014 Feb;14(2):92-107 PMID: 24457416
  14. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  15. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
    Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5808-12 PMID: 8016070
  16. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.
    Genome Res. 2012 Mar;22(3):568-76 PMID: 22300766
  17. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.
    Clin Cancer Res. 2013 Apr 1;19(7):1816-26 PMID: 23401227
  18. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice.
    Science. 2012 Nov 23;338(6110):1080-4 PMID: 23087000
  19. The somatic genomic landscape of glioblastoma.
    Cell. 2013 Oct 10;155(2):462-77 PMID: 24120142
  20. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
    Brain Pathol. 2009 Jan;19(1):81-90 PMID: 18452568
  21. Tumor immunotherapy directed at PD-1.
    N Engl J Med. 2012 Jun 28;366(26):2517-9 PMID: 22658126
  22. Discovery and saturation analysis of cancer genes across 21 tumour types.
    Nature. 2014 Jan 23;505(7484):495-501 PMID: 24390350
  23. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy.
    Curr Opin Oncol. 2013 Jan;25(1):50-1 PMID: 23150341
  24. Genetically engineered mouse models of diffuse gliomas.
    Brain Res Bull. 2012 May 1;88(1):72-9 PMID: 21684324
  25. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.
    Cell. 2013 Nov 7;155(4):948-62 PMID: 24183448
  26. p53, the cellular gatekeeper for growth and division.
    Cell. 1997 Feb 7;88(3):323-31 PMID: 9039259
  27. The ImageJ ecosystem: An open platform for biomedical image analysis.
    Mol Reprod Dev. 2015 Jul-Aug;82(7-8):518-29 PMID: 26153368
  28. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  29. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
    Cell. 2016 Jan 28;164(3):550-63 PMID: 26824661
  30. The Sequence Alignment/Map format and SAMtools.
    Bioinformatics. 2009 Aug 15;25(16):2078-9 PMID: 19505943
  31. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 PMID: 9776413
  32. Genetic screens in human cells using the CRISPR-Cas9 system.
    Science. 2014 Jan 3;343(6166):80-4 PMID: 24336569
  33. The 2007 WHO classification of tumours of the central nervous system.
    Acta Neuropathol. 2007 Aug;114(2):97-109 PMID: 17618441
  34. The tumor suppressor p53: cancer and aging.
    Cell Cycle. 2008 Apr 1;7(7):842-7 PMID: 18414039
  35. Generation of murine xenograft models of brain tumors from primary human tissue for in vivo analysis of the brain tumor-initiating cell.
    Methods Mol Biol. 2014;1210:37-49 PMID: 25173159
  36. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Sci Signal. 2013 Apr 02;6(269):pl1 PMID: 23550210
  37. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
    Oncotarget. 2015 Dec 22;6(41):43452-71 PMID: 26496030
  38. p53 mutations in cancer.
    Nat Cell Biol. 2013 Jan;15(1):2-8 PMID: 23263379
  39. Applications of the CRISPR-Cas9 system in cancer biology.
    Nat Rev Cancer. 2015 Jul;15(7):387-95 PMID: 26040603
  40. Development of a novel mouse glioma model using lentiviral vectors.
    Nat Med. 2009 Jan;15(1):110-6 PMID: 19122659
  41. Validation of housekeeping genes for gene expression analysis in glioblastoma using quantitative real-time polymerase chain reaction.
    Brain Tumor Res Treat. 2015 Apr;3(1):24-9 PMID: 25977903
  42. BamTools: a C++ API and toolkit for analyzing and managing BAM files.
    Bioinformatics. 2011 Jun 15;27(12):1691-2 PMID: 21493652
  43. BEDTools: a flexible suite of utilities for comparing genomic features.
    Bioinformatics. 2010 Mar 15;26(6):841-2 PMID: 20110278
  44. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
    Nature. 2008 Oct 23;455(7216):1061-8 PMID: 18772890
  45. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  46. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.
    Cell. 2015 Mar 12;160(6):1246-60 PMID: 25748654
  47. Precision medicine for cancer with next-generation functional diagnostics.
    Nat Rev Cancer. 2015 Dec;15(12):747-56 PMID: 26536825
  48. Integrated genomic characterization of IDH1-mutant glioma malignant progression.
    Nat Genet. 2016 Jan;48(1):59-66 PMID: 26618343
  49. 3D Slicer as an image computing platform for the Quantitative Imaging Network.
    Magn Reson Imaging. 2012 Nov;30(9):1323-41 PMID: 22770690
  50. Global microRNA depletion suppresses tumor angiogenesis.
    Genes Dev. 2014 May 15;28(10):1054-67 PMID: 24788094
  51. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Nat Genet. 2000 Sep;26(1):109-13 PMID: 10973261
  52. Multiplex genome engineering using CRISPR/Cas systems.
    Science. 2013 Feb 15;339(6121):819-23 PMID: 23287718
  53. Genome-scale CRISPR-Cas9 knockout screening in human cells.
    Science. 2014 Jan 3;343 (6166):84-87 PMID: 24336571
  54. Fast and accurate short read alignment with Burrows-Wheeler transform.
    Bioinformatics. 2009 Jul 15;25(14):1754-60 PMID: 19451168
  55. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
    Nat Protoc. 2009;4(1):44-57 PMID: 19131956
  56. RNA-guided human genome engineering via Cas9.
    Science. 2013 Feb 15;339(6121):823-6 PMID: 23287722
  57. Gliomagenesis: genetic alterations and mouse models.
    Nat Rev Genet. 2001 Feb;2(2):120-9 PMID: 11253051
  58. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.
    Cancer Cell. 2009 Jan 6;15(1):45-56 PMID: 19111880
  59. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.
    Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17450-5 PMID: 21969599
  60. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001.
    Cancer. 2006 Mar 15;106(6):1358-63 PMID: 16470608
  61. ARL6IP1 mediates cisplatin-induced apoptosis in CaSki cervical cancer cells.
    Oncol Rep. 2010 May;23(5):1449-55 PMID: 20372863
  62. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
    Cancer Cell. 2010 Jan 19;17(1):98-110 PMID: 20129251
  63. CRISPR-Cas9 knockin mice for genome editing and cancer modeling.
    Cell. 2014 Oct 9;159(2):440-55 PMID: 25263330
  64. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.
    Nucleic Acids Res. 2010 Sep;38(16):e164 PMID: 20601685
  65. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10 ):987-96 PMID: 15758009
  66. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
    Science. 2012 Aug 17;337(6096):816-21 PMID: 22745249
Article Info
Journal
Nature neuroscience
Abbr.
Nat Neurosci
ISSN
1546-1726
Published
2017-10-00
Epub
2017-00-14
Pages
1329-1341
Language
English
Region
United States
NLM ID
9809671
PMCID
PMC5614841
Subset
IM
Grants
NCI NIH HHS · U54 CA209992 · United States
NIMH NIH HHS · R01 MH110049 · United States
NCI NIH HHS · R01 CA133404 · United States
NIMH NIH HHS · DP1 MH100706 · United States
NIGMS NIH HHS · R01 GM034277 · United States
NIGMS NIH HHS · T32 GM007205 · United States
NIGMS NIH HHS · T32 GM007499 · United States
NCI NIH HHS · P50 CA196530 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com